MARKET

MEDP

MEDP

Medpace Holdings
NASDAQ

Real-time Quotes | Nasdaq Last Sale

133.32
-0.40
-0.30%
Closed 16:47 05/24 EDT
OPEN
131.59
PREV CLOSE
133.72
HIGH
134.14
LOW
130.38
VOLUME
339.75K
TURNOVER
--
52 WEEK HIGH
231.00
52 WEEK LOW
126.95
MARKET CAP
4.49B
P/E (TTM)
24.91
1D
5D
1M
3M
1Y
5Y
Abbott (ABT) Transcatheter Valve Devices' Study Data Favorable
Abbott's (ABT) study data presented at EuroPCR 2022 reinforces the company's commitment to offering structural heart solutions, supported by clinical evidence that exceeds existing standards of care.
Zacks · 19h ago
Thermo Fisher (TMO) to Advance Precision Medicine in Qatar
Thermo Fisher's (TMO) collaboration with Qatar Genome Program will utilize the power of genomics to enhance the standard of healthcare for the Qatari population.
Zacks · 19h ago
CROs ICON, IQVIA, and Syneos Health initiated at buy at Guggenheim
Guggenheim has initiated coverage of five contract research organizations (CROs) and recommends three -- ICON plc (NASDAQ:ICLR), IQVIA Holdings (NYSE:IQV), and Syneos Health (NASDAQ:SYNH) -- as buys. The firm sees
Seekingalpha · 19h ago
Illumina's (ILMN) Innovations Drive Growth, Cost Woes Linger
Illumina (ILMN) is working on its goals to strengthen its foothold in the multi-billion gene sequencing market with some highly competitive products in its existing portfolio and pipeline.
Zacks · 21h ago
--Guggenheim Initiates Coverage on Medpace Holdings With Neutral Rating
MT Newswires · 1d ago
Here's Why Investors Should Retain Haemonetics (HAE) For Now
Investors are optimistic about Haemonetics's (HAE) better-than-expected results and robust segmental performance.
Zacks · 1d ago
Alcon (ALC) Signs EYSUVIS-Buyout Deal With Kala Pharmaceuticals
The acquisition of EYSUVIS complements Alcon's (ALC) Systane family of eye drops offering, strengthening its treatment options for dry eye disease.
Zacks · 1d ago
Here's Why You Should Hold on to Exact Sciences (EXAS) Stock
Investors are optimistic about Exact Sciences (EXAS) on impressive Q1 results and a bullish 2022 outlook.
Zacks · 1d ago
More
No Data
Learn about the latest financial forecast of MEDP. Analyze the recent business situations of Medpace Holdings through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

25.00%Strong Buy
0.00%Buy
75.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average MEDP stock price target is 140.00 with a high estimate of 151.00 and a low estimate of 129.00.
High151.00
Average140.00
Low129.00
Current 133.32
EPS
Actual
Estimate
0.420.841.271.69
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 497
Institutional Holdings: 32.47M
% Owned: 96.49%
Shares Outstanding: 33.65M
TypeInstitutionsShares
Increased
122
1.20M
New
69
332.31K
Decreased
149
1.26M
Sold Out
19
53.84K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Chairman/Chief Executive Officer/Director
August Troendle
President
Jesse Geiger
Chief Financial Officer/Treasurer
Kevin Brady
Executive Vice President
Susan Burwig
General Counsel/Secretary
Stephen Ewald
Lead Director/Independent Director
Fred Davenport
Independent Director
Brian Carley
Independent Director
Ashley Keating
Independent Director
Thomas King
Independent Director
Robert Kraft
Independent Director
Cornelius McCarthy
No Data
No Data
About MEDP
Medpace Holdings, Inc. is a provider of clinical research-based drug and medical device development services. The Company partners with pharmaceutical, biotechnology, and medical device companies in the development and execution of clinical trials. The Company's drug development services focus on full-service Phase I-IV clinical development services and include development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support. The Company also provides bio-analytical laboratory services, clinical human pharmacology, imaging services and electrocardiography reading support for clinical trials. The Company's operations are principally based in North America, Europe, and Asia.

Webull offers kinds of Medpace Holdings Inc stock information, including NASDAQ:MEDP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MEDP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MEDP stock methods without spending real money on the virtual paper trading platform.